This is important, since high-dose myeloablative chemotherapy has been abandoned in breast cancer treatment [3,31,32], although a small survival advantage has been reported for HER2-negative breast cancer in a recent meta-analysis [33]. This evidence concerns the gene ERBB2 and breast cancer.